{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '9. Since your last study visit, did you have any visits to a specialist physician (e.g.,', 'oncologist, rheumatologist, endocrinologist, orthopedic surgeon, etc.)?', 'No', 'Yes (if yes, go to 10)', '10. How many visits have you had to a specialist physician (e.g., oncologist, rheumatologist,', 'endocrinologist, orthopedic surgeon, etc.)?', '14 Sep 2020', 'Astellas', 'Page 115 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '12.8', 'RECIST V1.1', 'Table 1 - Time point response: patients with target (+/-', 'non-target) disease.', 'Target lesions Non-target lesions', 'New', 'Overall', 'lesions', 'response', 'CR', 'CR', 'No', 'CR', 'CR', 'Non-CR/non-PD', 'No', 'PR', 'CR', 'Not evaluated', 'No', 'PR', 'PR', 'Non-PD or', 'No', 'PR', 'not all evaluated', 'SD', 'Non-PD or', 'No', 'SD', 'not all evaluated', 'Not all', 'Non-PD', 'No', 'NE', 'evaluated', 'PD', 'Any', 'Yes or No', 'PD', 'Any', 'PD', 'Yes or No', 'PD', 'Any', 'Any', 'Yes', 'PD', 'CR = complete response, PR = partial response, SD = stable disease,', 'PD = progressive disease, and NE = inevaluable.', 'Table 2 - Time point response: patients with non-target', 'disease only.', 'Non-target lesions', 'New lesions', 'Overall response', 'CR', 'No', 'CR', 'Non-CR/non-PD', 'No', 'Non-CR/non-PDa', 'Not all evaluated', 'No', 'NE', 'Unequivocal PD', 'Yes or No', 'PD', 'Any', 'Yes', 'PD', 'CR = complete', 'response,', 'PD = progressive', 'disease,', 'and', 'NE = inevaluable.', 'a', \"'Non-CR/non-PD' is preferred over 'stable disease' for non-target\", 'disease since SD is increasingly used as endpoint for assessment', 'of efficacy in some trials so to assign this category when no', 'lesions can be measured is not advised.', '14 Sep 2020', 'Astellas', 'Page 116 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Table 3 - Best overall response when confirmation of CR and PR required.', 'Overall response', 'Overall response', 'BEST overall response', 'First time point', 'Subsequent time point', 'CR', 'CR', 'CR', 'CR', 'PR', 'SD, PD or PR', 'CR', 'SD', 'SD provided minimum criteria for SD duration met, otherwise, PD', 'CR', 'PD', 'SD provided minimum criteria for SD duration met, otherwise, PD', 'CR', 'NE', 'SD provided minimum criteria for SD duration met, otherwise NE', 'PR', 'CR', 'PR', 'PR', 'PR', 'PR', 'PR', 'SD', 'SD', 'PR', 'PD', 'SD provided minimum criteria for SD duration met, otherwise, PD', 'PR', 'NE', 'SD provided minimum criteria for SD duration met, otherwise NE', 'NE', 'NE', 'NE', 'CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, and NE = inevaluable', 'a If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease meeting PR criteria relative to baseline,', 'makes the disease PD at that point (since disease must have reappeared after CR). Best response would depend on whether minimum duration', 'for SD was met. However, sometimes \"CR\\' may be claimed when subsequent scans suggest small lesions were likely still present and in fact the', 'patient had PR, not CR at the first time point. Under these circumstances, the original CR should be changed to PR and the best response is PR.', 'Reproduced from: Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.', 'New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1).', 'Eur', 'J Cancer. 2009;45:228-47.', '14 Sep 2020', 'Astellas', 'Page 117 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}